“In 2024, we made significant strides across our portfolio, particularly with our Enzyme Transport Vehicle programs, achieving a path to a potential accelerated approval for our lead program in MPS II,” said Ryan Watts, CEO of Denali. “In 2025, we will continue expanding our capabilities as we prepare for our first potential product launch of tividenofusp alfa. In addition, we are prioritizing opportunities to expand and accelerate our TV portfolio and aim to advance one to two programs to the clinic annually.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics files automatic mixed securities shelf
- Denali Therapeutics initiated with a Buy at Deutsche Bank
- Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II
- Denali Therapeutics Outlines 2025 Milestones and Strategies
- Denali Therapeutics announces U.S. FDA BTD granted for tividenofusp